BioSpace News Archive

First public trial of DnaNudge’s technology has today been launched to study effects of DNA-based food choices for pre-diabetic individuals

It’s prudent to be aware of certain types of questions that -- while perhaps valid -- just don’t belong in this particular professional encounter and, in fact, could harm your candidacy and reflect negatively on your reputation if asked.

Buried deep in an announcement touting a 6 percent growth in net sales driven by strong revenue gains of Cosentyx, Swiss pharma giant Novartis reported it received a Complete Response Letter from the U.S. Food and Drug Administration for canakinumab as a potential treatment for cardiovascular risk reduction.

Another scientific paper has been retracted by the New England Journal of Medicine. The noted journal said it retracted a paper on evidence of human lung stem cells following an investigation that revealed images used in the article had been manipulated.

As a valued member of our BioSpace community, we are eager to hear more from you and other readers. Name one influencer in the life sciences industry that produced a significant impact in 2018.

Weeks after Waltham, Mass.-based Morphic Therapeutic secured $80 million in Series B financing that was supported in part by AbbVie Ventures, the company struck a deal with the pharma giant to collaborate on the development of therapies for fibrosis-related indications.

TIME Magazine came out with a list of the 50 most influential people in healthcare, dubbed The Health Care 50. A look through the list shows just how many ties and connections—as well as influence—this group has on the biopharma industry.

VisionGate, Inc. is pleased to announce the appointment of R. John Glasspool as its Chief Operating and Strategy Officer.

Pelareorep and FOLFIRI/B combination shows superior OS & PFS data in KRAS mutant colorectal cancer compared to historical data

Eisai Co., Ltd. has announced that the National Medical Products Administration of China has accepted for review a New Drug Application for Eisai’s antiepileptic drug (AED) perampanel as an adjunctive treatment for partial onset seizures in epilepsy patients 12 years of age and older. This NDA is the first to be submitted for perampanel in China.